Introduction {#s1}
============

Autism spectrum disorder (ASD) is a neurodevelopmental disorder (NDD) characterized by impaired social interaction and communication together with repetitive and restrictive behaviors ([@B1]). The estimated prevalence of ASD stands at approximately 1% in the general population, and this value is influenced by whether adult or child and adolescent populations are considered ([@B27]).

ASD is a multifactorial disorder, meaning that several factors (both environmental and genetic) are involved in the development of this condition. Thus, rare genetic variation, including small deletions and duplications (indels), CNVs (*copy number variation*) and SNVs (*single-nucleotide variation*) contribute significantly to ASD liability. In addition, the pattern of inheritance (common or rare) and the origin of these mutations (inherited or *de novo*) will also differentially contribute to the genetic risk. Thus, rare inherited variation (*MAF* \< 1%) alone only explains 3% of ASD genetic risk ([@B23]). However, common variation accounts for a substantial fraction of ASD heritability (50%) ([@B8]; [@B26]; [@B13]; [@B3]). Early GWAS of ASD have failed to detect strong signals which could possibly be due to the presence of phenotypic heterogeneity across collections and the need of much larger sample sizes to achieve an adequate statistical power ([@B32]; [@B2]; [@B22]). Different associated signals were considered as plausible risk variants for years even when subsequent studies did not replicate most of them. Thus, some examples of associated SNPs (*single-nucleotide polymorphisms*) are the following: rs10513025 (*SEMA5A*), rs4141463 (*MACROD2*), and rs4307059 (*MSNP1*), among others ([@B32]; [@B18]; [@B17]; [@B28]). However, the genetic landscape of ASD has evolved over the past 10 years, and the latest ASD GWAS meta-analysis conducted by the Psychiatric Genomic Consortium (PGC) is a proof of that. PGC has made an incredible effort not only to increase sample size up to 10,000 cases and controls but also to develop well-defined quality control and imputation pipelines. The latest ASD GWAS meta-analysis has led to the identification of 93 genome-wide significant markers of which only 53 were replicated in independent cohorts. Top associated SNPs were rs910805 (chromosome 20; p-value: 2.04 × 10^−9^) and rs10099100 (chromosome 8; p-value: 1.07 × 10^−8^), among others ([@B15]). However, GWAS information can be also analyzed following a gene-based analysis (GBA) approach. Thus, p-values for each SNP within a gene are combined to obtain a single statistic for each single gene across the genome ([@B16]). GBA strategies employ summary statistics from GWAS without the need of individual genotypes. The study of genes as testing units with a biological entity provides the correct framework to carry out secondary approaches. These additional studies help to characterize the molecular and cellular mechanisms involved in the pathogenesis of the disease ([@B31]).

MAGMA is one of the most commonly used GBA methods together with VEGAS. ([@B10]; [@B21]). Thus, the latest ASD GWAS meta-analysis includes an additional GBA done by MAGMA. The top associated genes reported in this study were *KIZ* and *XRN2* (chromosome 20), *MFHAS1*, *XKR6*, *MSRA*, and *SOX7* (chromosome 8). The remaining associated genes were *KCNN2*, *KANSL1*, *MACROD2*, *WNT3*, *MAPT*, *CRHR1*, *NTM*, *MMP12*, and *BLK* ([@B15]).

PASCAL (*Pathway scoring algorithm*) is one of the most recent GBA approaches. PASCAL generates gene scores by aggregating SNP p-values from GWAS meta-analysis while correcting for LD (*linkage disequilibrium*) using 1000 Genomes data. Thus, PASCAL creates a pairwise SNP by SNP correlation matrix. MAGMA also allows to correct by LD structure but in a different way. It creates a SNP matrix (principal components) pruning away those SNPs presenting small eigenvalues in the matrix ([@B10]; [@B19]). Moreover, PASCAL is distinguishable from VEGAS and MAGMA by having more statistical power and by being computationally less demanding ([@B19]).

The main aim of this paper is to further mine the summary data from the meta-analysis of ASD by PASCAL. Although it is expected that the results do not vary much from those genes found by MAGMA, additional analysis will be performed to characterize the functional role of the ASD-associated genes. Therefore, gene-network analysis, enrichment analysis, and meta-analysis of DEG (different expressed genes) in ASD brain will be carried out to gain information about their biological function.

Methods {#s2}
=======

GWAS Meta-Analysis {#s2_1}
------------------

Summary statistics from the latest ASD GWAS meta-analysis were obtained from the public repository available in the PGC website (<http://www.med.unc.edu/pgc/results-and-downloads>). The following data set was employed: iPSYCH_PGC_ASD_Nov2017.gz ([@B15]) which includes the meta-analysis of ASD by the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH) and the Psychiatric Genomics Consortium (PGC) released in November 2017.

The data set comprises a total of 18,381 cases and 27,969 controls. Additional information including sample size and ancestry can be found in [**Table 1**](#T1){ref-type="table"}. Additional information about the genotyping and QC methods employed are available at the PGC website.

###### 

Characterization of ASD cohorts included in PGC GWAS meta-analyses.

  Study name                                                 Design study                             Sample size (cases/controls)   Ancestry   Diagnostic instrument                         Total (cases/controls)
  ---------------------------------------------------------- ---------------------------------------- ------------------------------ ---------- --------------------------------------------- ------------------------
  iPSYCH                                                     Case/control                             13076/22664                    European   ICD10 criteria                                18381/27969
  PGC                                                        UCLA Autism Center of Excellence (ACE)   Trio                           391/391    European                                      ADI-R and/or ADOS
   Autism Genome Proyect (AGP)                               Trio                                     2272/2272                      European   ADI-R and ADOS                                
  Autism Genetic Resource Exchange (AGRE)                    Trio                                     974/974                        European   ADI-R and ADOS                                
  NIMH Repository, the Montreal/Boston Collection (MOMBOS)   Trio                                     1396/1396                      European   ADI-R, Autism Screening questionnaire, ADOS   
  Simons Simplex Collection (SSC)                            Trio                                     2231/2231                      European   ADI-R and ADOS                                

ICD10, International Classification of Diseases, 10^th^ revision; ADI-R, Autism Diagnostic Interview---Revised; ADOS, Autism Diagnostic Observation Schedule.

Gene-Based-Analysis {#s2_2}
-------------------

PASCAL scoring algorithm (<https://www2.unil.ch/cbg/index.php?title=Pascal>) was applied to the summary statistics from ASD meta-analysis. Individual SNPs from GWAS results were first mapped to genes employing a default ±50 kb window around 5′ and 3′UTRs. The default maximum number of SNPs per gene allowed by PASCAL was 3,000. LD information was retrieved from 1000 Genomes European panel. Bonferroni correction sets the significance cutoff at 2.26 × 10^−6^ (0.05/22135 genes).

Regional Plots {#s2_3}
--------------

LocusZoom tool (<http://locuszoom.org/>) was employed to construct regional plots for the regions containing PASCAL associated genes. To this aim, meta-analysis data including marker name, p-values, odds ratio (OR), chromosome position (start-end), and index SNP were specified for the analysis. The source of LD information used to construct the r^2^ correlation matrix between SNPs in these regional plots was retrieved from hg19/1000 Genomes Nov 2014 EUR (European). The rest of the optional controls were used as default.

Gene-Network Analysis {#s2_4}
---------------------

FunCoup v.4.0 (<http://funcoup.sbc.su.se/search/>) was employed to expand the list of associated genes (p \< 2.26 × 10^−6^) including its interactors. FunCoup database integrates 10 different types of functional couplings among genes that allow to infer functional association networks: protein interaction (PIN), mRNA co-expression (MEX), protein co-expression (PEX), genetic interaction profile similarity (GIN), shared transcription factor binding (TFB), co-miRNA regulation by shared miRNA targeting (MIR), subcellular co-localization (SCL), domain interactions (DOM), phylogenetic profile similarity (PHP), and quantitative mass spectrometry (QMS). Gene networks for ASD were constructed considering as input six of the eight associated loci due to the lack of information for the remaining two ([**Table 2**](#T2){ref-type="table"}). Gene networks were constructed considering three different parameters. Therefore, expansion parameters include confidence threshold (0.8), a maximum number of 30 nodes per expansion step, and a query depth of 1 (only genes directly linked to the query genes are shown). Network expansion algorithm was settled in order to obtain those strongest interactors for any query gene, without prioritizing common neighbor's links. Moreover, enriched term analyses (KEGG, GO biological function, and GO molecular function) were considered for each gene network constructed with the corresponding p-values. Gene-network representation displays the most significant KEGG pathways according to their q-values after considering a FDR approach. Node sizes scales to emphasize gene importance in the whole network while participating nodes for each KEGG pathway are marked in black.

###### 

FunCoup interactors detected using PASCAL associated genes as input. Some PASCAL- associated genes have not been detected by FunCoup (bold font). Those genes for which one or several interactors were found are shown in the table. Last column indicates the type of functional coupling among genes used to construct the network. Moreover, some PASCAL- associated genes and interactors were not detected by FUMA (underlined genes).

  PASCAL analysis          Query genes for FunCoup   Interaction partners                                                                                                                                                                  Network
  ------------------------ ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------
  *XRN2*                   *XRN2*                    *DDX21,ILF2,CDKN2AIP,EXOSC8,NOC3L,ACIN1,ILF3,GNL3,[KNRNPF]{.ul},ADAR,LYAR,SNW1,[HNRNPK]{.ul},HNRNPH1,PARN,SUMO2,DHX15,NOP2,UPF1,ALYREF,RBM39,SYNCRIP,PTBP1,C14orf166,NONO,HNRNPUL1*   Complex and PPI
  *NKX2-4*                 *NKX2-2*                  *OLIG2*                                                                                                                                                                               PPI
  *KIZ*                    *KCNN2*                   *CALM1,CALM2,CALM3*                                                                                                                                                                   PPI
  *KCNN2*                                                                                                                                                                                                                                  
  *NKX2-2*                                                                                                                                                                                                                                 
  ***CRHR1-IT1***                                                                                                                                                                                                                          
  *C8orf74*                                                                                                                                                                                                                                
  ***[LOC644172]{.ul}***                                                                                                                                                                                                                   

Functional Annotation {#s2_5}
---------------------

GENE2FUNC, a core process of FUMA (*Functional Mapping and Annotation of Genome-Wide Association Studies*) (<http://fuma.ctglab.nl/>), was used to functionally annotate ASD genes and its interactors. Therefore, ASD input for FUMA comprises 36 genes (PASCAL associated genes plus strong interactors from FunCoup) ([**Table 2**](#T2){ref-type="table"}).

Different analyses performed by GENE2FUNC were employed, including a gene expression heatmap and an enrichment analysis of differentially expressed genes (DEG). Gene expression heatmap was constructed employing GTEx v7 (53 tissue types) and BrainSpan RNA-seq data. The average of normalized expression per label (zero means across samples) was displayed on the corresponding heatmaps. Expression values are TPM (Transcripts Per Million) for GTEx v7 and RPKM (Read Per Kilobase per Million) in the case of BrainSpan data set. Heatmaps display normalized expression value (zero mean normalization of log2 transformed expression), and darker red means higher relative expression of that gene in each label, compared to a darker blue color in the same label. DEG analysis was carried out creating differentially expressed genes for each expression data set. In order to define DEG sets, two-sided Student's t-test were performed per gene per tissue against the remaining labels (tissue types or developmental stages). Those genes with a p-value \< 0.05 after Bonferroni correction and a log fold change ≥ 0.58 are defined as DEG. The direction of expression was considered. The -log10 (p-value) refers to the probability of the hypergeometric test.

Meta-Analysis of Differentially Expressed Genes in ASD Studies {#s2_6}
--------------------------------------------------------------

dbMDEGA (<https://dbmdega.shinyapps.io/dbMDEGA/>) allows to conduct a meta-analysis using different ASD and brain control expression datasets to test which genes are differentially expressed (DEGs) between both groups. Specifically, this tool uses expression profiles from three human ASD brain gene expression datasets: GSE28475 ([@B7]), GSE28521 ([@B30]), and GSE38322 ([@B12]). Thus, dbMDEGA contains about 17,741 human genes as meta-results for querying DEGs. PASCAL genes and FunCoup interactors (N = 36) were submitted in the Meta_summary panel. Meta-analysis p-values (random effects model), FDR (false discovery rate) for each gene, and heterogeneity measures (I^2^) were obtained.

Results {#s3}
=======

Gene-Based-Analysis {#s3_1}
-------------------

PASCAL analysis has revealed association of eight loci (p-value \< 2.26 × 10^−6^) ([**Table 3**](#T3){ref-type="table"}). *NKX2-2* and *NKX2-4* (chromosome 20) were highlighted as associated by PASCAL in comparison with the results obtained by MAGMA ([**Table 4**](#T4){ref-type="table"}). Regional association plot around rs910805 shows three different r^2^ levels. PASCAL is able to detect *NKX2-2* and *NKX2-4* as associated, both genes located farther away from the lead SNP. However, SNPs within both loci are in moderate LD with the index SNP ([**Figure 1**](#f1){ref-type="fig"}). In addition, PASCAL shows association of *CRHR1-IT1*, *LOC644172* (chromosome 17), and *C8orf74* (chromosome 8) ([**Table 3**](#T3){ref-type="table"} and [**Figure 1**](#f1){ref-type="fig"}). It is worth to note that *CRHR1-IT1* is intronic with *CRHR1* (previously reported by MAGMA) ([**Table 4**](#T4){ref-type="table"}). However, the vast majority of loci associated by PASCAL were previously reported by MAGMA ([**Table 4**](#T4){ref-type="table"}).

###### 

Top 20 results reported by PASCAL for ASD GWAS meta-analysis data. Genes represented in bold surpass Bonferroni threshold (p-value \< 2.26 × 10^−^ ^6^). Columns show gene, chromosome, start and end positions for each gene, the number of SNPs included in the analysis for each gene, and their PASCAL p-values.

  Gene              Chromosome   Start position   End position   Number of SNPs   PASCAL p-value
  ----------------- ------------ ---------------- -------------- ---------------- ----------------
  ***XRN2***        chr20        21283941         21370463       271              3.53 × 10^−9^
  ***NKX2-4***      chr20        21376004         21378047       143              9.51 × 10^−9^
  ***PLK1S1***      chr20        21106623         21227258       287              4.69 × 10^−8^
  ***KCNN2***       chr5         113698015        113832197      540              3.89 × 10^−7^
  ***NKX2-2***      chr20        21491659         21494664       166              7.78 × 10^−7^
  ***CRHR1-IT1***   chr17        43716340         43723595       26               1.69 × 10^−6^
  ***C8orf74***     chr8         10530146         10558103       314              1.78 × 10^−6^
  ***LOC644172***   chr17        43677490         43679748       24               2.15 × 10^−6^
  *LRRC37A*         chr17        44372496         44415160       48               2.64 × 10^−6^
  *ARL17A*          chr17        44363861         44657088       64               2.82 × 10^−6^
  *KANSL1-AS1*      chr17        44270938         44274089       46               2.84 × 10^−6^
  *KANSL1*          chr17        44107281         44302740       153              3.07 × 10^−6^
  *MAPT-IT1*        chr17        43973148         43976164       50               3.68 × 10^−6^
  *SOX7*            chr8         10581277         10697299       752              4.84 × 10^−6^
  *MAPT*            chr17        43971747         44105699       100              4.86 × 10^−6^
  *CRHR1*           chr17        43697709         43913194       275              5.45 × 10^−6^
  *MAPT-AS1*        chr17        43920721         43972879       224              6.14 × 10^−6^
  *STH*             chr17        44076615         44077060       37               6.27 × 10^−6^
  *SPPL2C*          chr17        43922255         43924438       193              6.57 × 10^−6^
  *PINX1*           chr8         10622883         10697299       684              7.78 × 10^−6^

###### 

Significant genes reported by PASCAL and MAGMA algorithms. All significant genes reported in our study and Grove et al. publication are shown. Columns show chromosome, start and end positions for each gene, p-value reported by PASCAL or MAGMA, and the corresponding tag SNP for each gene.

  Gene                                                        Chromosome   Start position   End position   PASCAL/MAGMA p-value   Tag SNP
  ----------------------------------------------------------- ------------ ---------------- -------------- ---------------------- --------------
  **Results from PASCAL gene based analysis**                                                                                     
  *XRN2*                                                      20           21283941         21370463       3.53 × 10^−9^          rs 910805
  *NKX2-4*                                                    20           21376004         21378047       9.51 × 10^−9^          rs 910805
  *PLK1S1*                                                    20           21106623         21227258       4.69 × 10^−8^          rs 910805
  *KCNN2*                                                     5            113698015        113832197      3.89 × 10^−7^          rs 13188074
  *NKX2-2*                                                    20           21491659         21494664       7.78 × 10^−7^          rs 910805
  *CRHR1-IT1*                                                 17           43716340         43723595       1.69 × 10^−6^          rs 142920272
  *C8orf74*                                                   8            10530146         10558103       1.78 × 10^−6^          rs 10099100
  *LOC644172*                                                 17           43677490         43679748       2.15 × 10^−6^          rs 142920272
  **Results from MAGMA gene based analysis (** [@B15] **)**                                                                       
  *XRN2*                                                      20           21283942         21370463       9.69 × 10^−10^         rs 910805
  *KCNN2*                                                     5            113698016        113832197      1.02 × 10^−9^          rs 13188074
  *PLK1S1*                                                    20           21106624         21227260       5.17 × 10^−9^          rs 910805
  *MACROD2*                                                   20           13976146         16033842       1.40 × 10^−7^          rs 71190156
  *WNT3*                                                      17           44841686         44896082       4.03 × 10^−7^          rs 142920272
  *MAPT*                                                      17           43971748         44105700       5.01 × 10^−7^          rs 142920272
  *MFHAS1*                                                    8            8641999          8751131        5.58 × 10^−7^          rs 11249905
  *XKR6*                                                      8            10753654         11058875       8.01 × 10^−7^          rs 10099100
  *MSRA*                                                      8            9911830          10286401       9.15 × 10^−6^          rs 10099100
  *CRHR1*                                                     17           43697710         43913194       1.07 × 10^−6^          rs 142920272
  *SOX7*                                                      8            10581278         10588022       1.24 × 10^−6^          rs 10099100
  *NTM*                                                       11           131240371        132206716      1.32 × 10^−6^          rs 549507
  *MMP12*                                                     11           102733464        102745764      2.28 × 10^−6^          rs 102751102
  *BLK*                                                       8            11351521         11422108       2.45 × 10^−6^          rs 2736342

![Regional association plots for ASD GWAS meta-analysis (chromosomes 20, 8 and 7). PASCAL has highlighted associations at a gene level for *NKX2*-2 and *NKX2-4* (chr20), *CRHR1-IT1*, *LOC644172* (chr17), and *C8orf74* (chr8) among other genes previously associated by MAGMA.](fgene-10-00733-g001){#f1}

Gene-Network Analysis {#s3_2}
---------------------

FunCoup has detected several interactors for PASCAL associated loci ([**Table 2**](#T2){ref-type="table"}). Gene network for ASD genes was constructed after including 36 genes (30 subnetwork genes plus 6 query genes) and considering 120 links between them ([**Table 2**](#T2){ref-type="table"}). FunCoup was not able to detect interactors for the remaining ASD-associated loci. Enrichment analysis for KEGG and GO terms has shown association of different biological processes as spliceosome (q-value = 3 × 10^−4^), RNA transport (q-value = 2.8 × 10^−3^), and nucleic acid binding (q-value = 1.09 × 10^−14^) ([**Table 5**](#T5){ref-type="table"} and [**Figure 2**](#f2){ref-type="fig"}).

###### 

Enriched terms for query ASD genes and its interactors (subnetwork genes) according to FunCoup.

  Enriched terms                                                                                                                                                                                                                                                                Genes                                                                                                                                                                                                               q value
  ----------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  KEGG metabolic                                  Spliceosome                                                                                                                                                                                                                   *DH15, HNRNPK, ACIN1, ALYREF, SNW1*                                                                                                                                                                                 3 × 10^−4^
  RNA transport                                   *SUMO2, ACIN1, ALYREF, UPF1*                                                                                                                                                                                                  2.8 × 10^−3^                                                                                                                                                                                                        
  GO molecular function                           Nucleic acid binding                                                                                                                                                                                                          *DDX21, ILF2, CDKN2AIP, EXOSC8, NOC3L, ACIN1, ILF3, GNL3, KNRNPF, ADAR, LYAR, SNW1, HNRNPK, HNRNPH1,PARN, SUMO2, DHX15, NOP2, UPF1,ALYREF, RBM39, SYNCRIP, PTBP1, C14orf166, NONO,HNRNPUL1, XRN2, NKX2-4, NKX2-2*   1.09 × 10^−14^
  Heterocyclid compound binding                   *DDX21,ILF2,CDKN2AIP,EXOSC8,NOC3L,ACIN1,ILF3,GNL3,KNRNPF,ADAR,LYAR,SNW1,HNRNPK,HNRNPH1,PARN,SUMO2,DHX15,NOP2,UPF1,ALYREF,RBM39,SYNCRIP,PTBP1,C14orf166,NONO,HNRNPUL1,XRN2,NKX2-4,NKX2-2*                                      3.88 × 10^−10^                                                                                                                                                                                                      
  Organic cyclid compound binding                 *DDX21, ILF2, CDKN2AIP, EXOSC8, NOC3L, ACIN1, ILF3, GNL3, KNRNPF, ADAR, LYAR, SNW1, HNRNPK, HNRNPH1, PARN, SUMO2, DHX15, NOP2, UPF1, ALYREF, RBM39, SYNCRIP, PTBP1, C14orf166,NONO, HNRNPUL1, XRN2, NKX2-4, NKX2-2*           3.88 × 10^−10^                                                                                                                                                                                                      
  Protein binding                                 *DDX21, ILF2, CDKN2AIP, EXOSC8, ACIN1, ILF3, GNL3, KNRNPF, ADAR, LYAR, SNW1, HNRNPK, HNRNPH1, PARN, SUMO2, DHX15, NOP2, UPF1, ALYREF, RBM39, SYNCRIP, PTBP1,C14orf166, NONO, HNRNPUL1, XRN2, KCNN2, NKX2-2, KIZ, C8orf74*     9.94 × 10^−4^                                                                                                                                                                                                       
  Binding                                         *DDX21,ILF2,CDKN2AIP, EXOSC8, ACIN1,ILF3,GNL3, KNRNPF,ADAR,LYAR, SNW1,HNRNPK, HNRNPH1,PARN,SUMO2, DHX15,NOP2, UPF1, ALYREF, RBM39, SYNCRIP, PTBP1,C14orf166,NONO, HNRNPUL1, XRN2,KCNN2, NKX2-2,KIZ, C8orf74, NKX2-4, NOC3L*   2.81 × 10^−2^                                                                                                                                                                                                       
  Chromatin binding                               *NKX2-2, NONO, NOC3L, UPF1,*                                                                                                                                                                                                  1.03 × 10^−1^                                                                                                                                                                                                       
  Transcription factor binding                    *NKX2-2, HNRNPF, SUMO2, SNW1*                                                                                                                                                                                                 1.03 × 10^−1^                                                                                                                                                                                                       
  Enzyme binding                                  *KIZ, SUMO2,C14orf166, PARN, ACIN1, HNRN,UL1, SNW1*                                                                                                                                                                           2.54 × 10^−1^                                                                                                                                                                                                       
  Hydrolase activity, acting on acid anhydrides   *DHX15, DDX21,ACIN1,UPF1*                                                                                                                                                                                                     3.34 × 10^−1^                                                                                                                                                                                                       
  Identical protein binding                       *KCNN2, NONO, EXOSC8, C14orf166,OLIG2*                                                                                                                                                                                        4.21 × 10^−1^                                                                                                                                                                                                       
  hydrolase activity                              *XRN2, DHX15,ADAR, DDX21,PARN,ACIN1,UPF1*                                                                                                                                                                                     6.03 × 10^−1^                                                                                                                                                                                                       

![ASD gene networks constructed with PASCAL associated genes and its FunCoup interactors. Node sizes scale to emphasize gene importance in the whole network, while participating nodes for each KEGG pathway are marked in black: **(A)** cAMP signaling pathway; **(B)** RNA transport.](fgene-10-00733-g002){#f2}

Functional Annotation {#s3_3}
---------------------

### Gene Expression Heatmaps and Differential Expression Analysis {#s3_3_1}

Gene expression heatmap based on GTEX v7 RNA-seq data for ASD-associated genes together with FunCoup interactors ([**Table 2**](#T2){ref-type="table"}) has revealed interesting results. Specifically, three genes (*NKX2-2*, *OLIG-2*, and *KCNN2*) display increased expression levels in brain (different regions) in comparison with the remaining tissues included in the analysis. Moreover, another gene set, *XRN2* plus some interactors, display the opposite trend showing lower relative expression levels on brain tissues ([**Figure 3**](#f3){ref-type="fig"}). Interestingly, gene expression heatmap employing BrainSpan data has revealed that the vast majority of genes included on the downregulated gene-set have shown a higher relative expression in prenatal stages (early, early-mid, and late-mid). Moreover, the same trend was also observed for *NKX2-2* and *OLIG2*. Therefore, a lower relative expression level for these genes was shown across prenatal stages in comparison with those levels found in adult brain tissues ([**Figure 3**](#f3){ref-type="fig"}). Thus, there is a clear division in terms of expression levels for those sets of genes expressed across different pcw (post-conception weeks) *versus* those expressed across the adult lifespan. DEG analysis with GTEx data (adult brain) has shown significantly enriched DEG sets across distinct brain tissues. Moreover, DEG study performed with BrainSpan data has confirmed a significant association of gene sets during early prenatal stages (up-regulation) *versus* young adulthood (down-regulation). Specifically, up-regulation occurs around 8, 9, and 13 pcw, and down-regulation takes place across different postnatal ages ([**Figure 4**](#f4){ref-type="fig"}).

![ASD gene expression heatmaps constructed with GTEX v7 (53 tissues) (left) and BrainSpan 29 different ages of brain samples data (right). Genes and tissues are ordered by clusters for the GTEX heatmap. In the case of BrainSpan heatmap, genes are ordered by expression clusters, and neurodevelopmental stages are chronologically classified from prenatal to postnatal stages.](fgene-10-00733-g003){#f3}

![ASD DEG plots constructed with GTEX v7 (53 tissues) (left) and BrainSpan 29 different ages of brain samples data (right). Significantly enriched DEG sets (Pbon \< 0.05) are highlighted in red.](fgene-10-00733-g004){#f4}

Meta-Analysis of Differentially Expressed Genes in ASD Studies {#s3_4}
--------------------------------------------------------------

Expression meta-analysis for PASCAL associated genes has shown differentially expressed genes between ASD brain individuals and controls (*XRN2*, p-value = 0.02; *KCNN2*, p-value = 0.01; *C8orf74*; p-value = 0.03). Moreover, some of the *XRN2* interactors have also shown significant p-values when dbDMEGA analysis was performed (*XRN2*, *CDKN2AIP*, *ILF3*, *GNL3 ADAR*, *LYAR*, *SNW1*, *RBM39*, *SYNCRIP*, and *PTBP1*) ([**Table 6**](#T6){ref-type="table"}).

###### 

PASCAL associated genes and interactors. p-values from PASCAL and dbMDEGA meta-analysis are shown for each gene. p-values from dbMDEGA were computed using the p-value method. Heterogeneity values (I^2^) are also shown. (NA = the gene is not in dbMDEGA).

  Gene          p-val PASCAL          p-val dbMDEGA   FDR dbMDEGA   Heterogeneity
  ------------- --------------------- --------------- ------------- ---------------
  *XRN2*        3.52863316 × 10^−9^   0.02            0.12          0%
  *NKX2-4*      9.5086814 × 10^−9^    NA              NA            NA
  *PLK1S1*      4.68346333 × 10^−8^   NA              NA            NA
  *KCNN2*       3.88782618 × 10^−7^   0.01            0.11          0%
  *NKX2-2*      7.7773789 × 10^−7^    0.23            0.37          0%
  *CRHR1-IT1*   1.6858736 × 10^−6^    NA              NA            NA
  *C8orf74*     1.77348539 × 10^−6^   0.03            0.16          43%
  *LOC644172*   2.15004243 × 10^−6^   NA              NA            NA
  *DDX21*       8.86663103 × 10^−1^   0.3             0.41          69%
  *ILF2*        5.52756293 × 10^−1^   0.38            0.45          28%
  *CDKN2AIP*    8.21802658 × 10^−1^   0.04            0.17          0%
  *EXOSC8*      9.41352461 × 10^−2^   0.1             0.26          64%
  *NOC3L*       3.66793335 × 10^−1^   0.35            0.44          0%
  *ACIN1*       9.65129025 × 10^−1^   0.15            0.3           48%
  *ILF3*        1.0116456 × 10^−1^    0.01            0.1           66%
  *GNL3*        2.39022069 × 10^−3^   0.01            0.07          67%
  *KNRNPF*      NA                    NA              NA            NA
  *ADAR*        1.70702835 × 10^−2^   0.01            0.1           72%
  *LYAR*        2.30069599 × 10^−1^   0.03            0.15          0%
  *SNW1*        1.0892706 × 10^−1^    0.04            0.18          74%
  *HNRNPK*      3.13685174 × 10^−1^   NA              NA            NA
  *HNRNPH1*     6.07006486 × 10^−1^   NA              NA            NA
  *PARN*        9.01671731 × 10^−1^   0               0.03          79%
  *SUMO2*       8.85347296 × 10^−1^   0.27            0.39          72%
  *DHX15*       2.93250866 × 10^−1^   0.12            0.38          0%
  *NOP2*        7.85747107 × 10^−1^   NA              NA            NA
  *UPF1*        2.08668839 × 10^−1^   0.12            0.27          14%
  *ALYREF*      2.00036414 × 10^−1^   NA              NA            NA
  *RBM39*       2.90163509 × 10^−1^   0.06            0.2           18%
  *SYNCRIP*     2.62087002 × 10^−1^   0.01            0.08          0%
  *PTBP1*       9.27312631 × 10^−2^   0.02            0.13          0%
  *C14orf166*   2.91369259 × 10^−1^   0.36            0.44          58%
  *NONO*        NA                    0.18            0.33          32%
  *HNRNPUL1*    4.2805356 × 10^−1^    NA              NA            NA
  *CALM1*       3.30876236 × 10^−1^   0.4             0.46          27%
  *CALM2*       9.81305815 × 10^−1^   0.36            0.44          0%
  *CALM3*       7.91761032 × 10^−1^   0.5             0.5           0%
  *OLIG2*       4.52957535 × 10^−1^   0.4             0.46          0%

Discussion {#s4}
==========

The latest ASD GWAS meta-analysis has reported the association of individual SNPs across chromosome 20 (rs910805), 5 (rs13188074), 17 (rs142920272), and 8 (rs10099100), among others. In the same study, different genes located near to the top-ranked SNPs as *XRN2*, *KCNN2*, and *KIZ* (or *PLK1S1*) have been associated by MAGMA ([@B15]). PASCAL analysis has shown additional associated genes: *NKX2-4*, *NKX2-2*, *CRHR1-IT1*, *C8orf74*, and *LOC644172*. However, these findings should not be considered as completely new. Thus, it is worth noting that lead SNPs located on chromosome 20 and 8 were associated with ASD when MTAG (*multi-trait analysis of GWAS*) was done with genetically correlated phenotypes (schizophrenia and educational attainment) but not by MAGMA itself ([@B29]; [@B15]). In fact, this is why *NKX2-4* and *NKX2-2* were reported as "possibly associated" genes when MTAG was carried out ([@B15]). However, we found that PASCAL is able to rescue these associations when its own statistical approach is applied. It is also worth to note that *CRHR1-IT1* partially overlap with *CRHR1* even if it encodes a different transcript (previously not reported by MAGMA). Thus, *CHR1-IT1* is reported as associated by PASCAL due to the inclusion of the "gene-name" in the list used as input (present in PASCAL and not in MAGMA). c*8orf74* could also be a controversial "new" finding because the SNPs located within the gene harbor more significant p-values but are located near to *XKR6* (identified in [@B15]). Even so, it should be considered that PASCAL has helped to unveil the association of additional genes near to those genes reported by MAGMA. Both GBA tools, MAGMA and PASCAL, work in a very similar way: i) they are able to employ summary statistics as input instead of genotypes, ii) gene scores are calculated combining the results for all SNPs located across the gene, and iii) LD correction is made by external information from the 1000 Genomes European panel ([@B10]; [@B19]). However, the construction of the correlation matrix is slightly different between both methods. This could explain those small differences found between the associated genes reported by both methods. p-values associated to each gene in PASCAL were in general less significant than those reported by MAGMA, even when identical genes were reported by both algorithms. Moreover, the number of genes that remain significant after Bonferroni correction was lower in PASCAL. All these results taken together could indicate that PASCAL is more conservative than MAGMA. In addition, we propose that PASCAL could be used as a complementary GBA approach because it has helped to highlight additional genes located in the same LD region than those reported by MAGMA.

Regarding the insight into the biological role of ASD-associated genes, we would like to focus on the following loci: *NKX2-2*, *NKX2-4*, *CRHR1-IT1*, *LOC644172*, and *c8orf74*. *NKX2-2* and *NKX2-4* are members of the homeobox-transcription factor family. *NKX2-2* encodes a transcription factor involved in the morphogenesis of the central nervous system, and it is essential during the differentiation of neural populations located on the hindbrain and spinal cord during early development ([@B5]). *NKX2-4* (*Homeobox Protein Nkx-2.4*) has a key role in brain development, and its downregulation in the developing forebrain promotes proliferation and inhibits differentiation of neural progenitors which results in impaired neurogenesis ([@B24]). Gene expression heatmaps (GTEX and BrainSpan data) have revealed two expression clusters in which *NKX2-2* is involved. Genes within the first cluster have shown downregulation across early prenatal stages and upregulation during postnatal stages, and genes within the second cluster have shown the opposite trend. *NKX2-2* and its interactor *OLIG-2* (*oligodendrocyte transcription factor 2*) are included in the first cluster that displays a lower normalized expression during prenatal stages in comparison with postnatal stages. This seems to point to the existence of a different genetic regulation for *NKX2-2* during brain development in comparison with the adult brain. Thus, it was reported that *NKX2-2* is initially expressed in differentiating oligodendrocyte precursor cells (OPCs) and then is downregulated. However, it was demonstrated that its expression could also be upregulated again during later neurodevelopmental stages in order to maintain myelin structures ([@B6]). This is particularly interesting due to previous reports that have linked aberrant expression of genes across the oligodendrocyte lineage with ASD pathology ([@B20]; [@B33]). In addition, enriched terms for *NKX2-2* and *OLIG-2* were protein, chromatin, and TF binding, all of them biological processes involved in ASD pathogenesis. However, it should be noted that both genes did not show differences in expression between ASD brain tissue and controls when DEG was carried out. These results indicate the need of subsequent functional studies to further characterize their biological role.

In addition, a second ASD expression cluster (BrainSpan heatmap) includes *XRN2*, *CRHR1-IT1*, and their multiple interactors. First of all, it should be remarked that FunCoup calculates many more interactors for *XRN2* than for the remaining genes. This could entail a bias for subsequent analysis but also underlines the relevance of this gene due to its wide PPI network. Thus, it is worth to note that many *XRN2* and some of its interactors (*CDKN2AIP*, *ILF3*, *GNL3 ADAR*, *LYAR*, *SNW1*, *RBM39*, *SYNCRIP*, and *PTBP1*) have shown significant p-values when dbMDEGA meta-analysis was performed. This fact demonstrates that these genes are differentially expressed between ASD brains and controls and therefore their potential relevance in ASD pathogenesis ([@B30]; [@B7]; [@B12]). In addition, some of the enriched terms for *XNR2* and their interactors were spliceosome, RNA transport, and nucleic acid binding, all of them essential biological functions with a role during early development. Thus, it was demonstrated that *XRN2* might serve a general role in triggering the termination of transcription through the degradation of the 3′ UTR ([@B11]). *CRHR1-IT1* codifies for a long intergenic non-protein coding RNA which was recently associated with susceptibility to antisocial behavior ([@B9]). *CRHR1-IT1* shares part of its sequence with *CRHR1* which encodes the corticotropin-releasing hormone receptor 1 ([@B15]). *CRHR1* is a main component of the hypothalamic-pituitary-adrenal pathway, and it has been repeatedly associated with response to stress-related psychopathology ([@B4]). The function of *CRHR1-IT1* is not well characterized, but it might play a role in the regulation of *CRHR1* expression. Thus, *CRHR1* and *CRHR1-IT1* could be involved in the modulation of behavior and cognition, both core features of ASD ([@B25]; [@B14]; [@B9]; [@B34]). However, the meta-analysis of DEG in ASD brain *vs* controls has not revealed association for *CRHR1* nor *CRHR1-IT1*.

Finally, *C8orf74* and *LOC644172* were also associated after PASCAL analysis. *LOC644172* is located upstream of *CRHR1* and *CRHR1-IT1*, but it was not recognized by FunCoup nor FUMA. *C8orf74* is part of a reading frame that has the ability to be translated, but it is not yet characterized. Thus, it seems that both loci are not included in functional and genetic databases due to their poor biological characterization. However, the meta-analysis of expression profiles revealed that *C8orf74* was differentially expressed between ASD brain tissues and controls, which indicates that *C8orf74* needs further functional characterization.

Conclusions {#s5}
===========

PASCAL algorithm was used to carry out a novel GBA of ASD, employing summary statistics from the latest GWAS meta-analysis. This study has identified several gene associations even though most of them were previously reported by MAGMA. However, PASCAL has been useful to define the association of other genes located in the same LD region than those found by MAGMA. These results indicate that PASCAL should be considered as a complementary GBA approach when it is necessary to further mine GWAS results.

The second part of this study has been focused on the biological characterization of the ASD-associated genes by PASCAL. Thus, gene-network and functional annotation approaches including gene expression heatmaps and DEG were carried out. This has helped to understand the genetic findings into a biological context and to select the most suitable ASD susceptibility genes as candidates for functional biological studies.
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